Similarly, the Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) study[59] reported that after treatment with 40 mg of pravastatin vs. 80 mg of atorvastatin CRP levels were reduced 0.7 and 0.8 mg/L after 30 days and four months, respectively, and that these declines resulted in CVD event rate reductions equivalent to what was observed for patients who achieved LDL-cholesterol treatment goals. This evidence concerns the gene CRP and infection.